



BIOTECH GROWTH TRUST:

Investment in innovation and opportunity

Frostrow
CAPITAL

orbimed

The Biotech Growth Trust offers investors a unique opportunity to gain exposure to one of the most dynamic and rapidly evolving sectors of the global economy.

The Trust specialises in investing in a portfolio of growth-stage biotech businesses at the cutting edge of medical innovation that are sector leaders with first-mover advantages in key treatments for the future.

The portfolio is managed by OrbiMed, a leading global healthcare investment firm with deep expertise in biotechnology. It offers investors access to pioneering companies addressing tomorrow's medical challenges—advancing solutions in areas like central nervous system disorders, oncology, cardiovascular disease, and gene and cell therapies.

WHY BIOTECH GROWTH TRUST?



Sector expertise: A leading team with a blend of technical and investment expertise in the biotech sector. The team boasts over 300 years of investment experience and comprises more than 30 qualified analysts with either an MD or PhD degree.



Global reach: A presence in multiple countries, enabling access to a broad spectrum of investment opportunities across international markets.



Integrated venture capital capabilities: A strong venture capital arm at OrbiMed that enhances deal sourcing and provides early access to some of the most promising emerging companies in the sector.



Diversified portfolio in cutting-edge sectors: The Trust's portfolio covers some of the leading biotech companies from across the globe.



Proven track record: The Biotech Growth Trust has invested in some of the world's leading biotech firms that have gone on to make strong returns for its investors. These include Immunomedics, Vertex Pharmaceuticals and Argenx.

THE GROWTH INVESTMENT OPPORTUNITY

The Biotech Growth Trust is structured to invest in innovative products that have the potential to revolutionise healthcare and significantly enhance the quality of life worldwide. With a diversified portfolio, expert management and a proven track record of investing in transformative companies, the Trust is well-positioned to deliver long-term capital appreciation for shareholders.

WHY BIOTECH?



Demographic tailwinds: An ageing global population is driving increased demand for innovative treatments and healthcare solutions around the world.



Breakthrough therapies on the horizon: The coming years are expected to bring significant advancements in the treatment of major conditions, such as Alzheimer's disease, cancer and obesity.



Strategic importance to the pharmaceutical industry: As large pharmaceutical companies see more patents expiring, they are turning to the acquisition of innovative biotech firms to replenish their patent pipelines, creating attractive exit opportunities for investors in these companies.



Biotech M&A is poised to accelerate: A diverse set of drivers – with biotech valuations at historic lows and innovation at an all-time high - coupled with the pressure of drug price reform on large pharma – means the sector is expected to see a rise in biotech take-outs.



Political priority for the U.S. government: The Trump Administration views the biotech sector as a strategically important industry and wants to reduce the regulatory hurdles for drug approvals to speed up the drug development process.



Undervalued Assets: The political and economic landscape has created a compelling entry point: valuations are attractive, and the pace of innovation and medical demand is at an all-time high, positioning the sector for sustained future growth.

RISK WARNINGS

This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Company and has not been prepared in connection with any such offer or invitation. Before investing in the Company, or any other investment product, you should satisfy yourself as to its suitability and the risks involved, and you may wish to consult a financial adviser.

Any return you receive depends on future market performance and is uncertain. The Company does not seek any protection from future market performance so you could lose some or all of your investment. For information on the principal risks the Company is exposed to please refer to the Company's Annual Report or Investor Disclosure Document available at <https://www.biotechgt.com/>